Search results for: Antibiotics

OHE Models Incentives for Antibiotic Drug Development

18 March 2014

The OHE model takes into account the value to society of new antibiotics as well as the risks and rewards for payers and the entities developing the new drugs. A…

Proposals for a Novel UK Antimicrobial Subscription Model: How Will Antibiotic Innovation be Scored?

8 November 2023

…needed antibiotics. Share this: Download publication New antibiotics are urgently needed, but their development is hindered by market failure. A ‘volume-delinked model’ subscription approach has been suggested to overcome this…

Proposals for a Novel UK Antimicrobial Subscription Model: The Investor Perspective

2 November 2023

…proposed pull incentive for antibiotic development in the UK by seeking the perspectives of (potential) investors in the antibiotics space. Investors are key stakeholders in the development of new antibiotics,…

HTA and Payment Mechanisms for New Drugs to Tackle AMR

1 September 2019

…from investment in antibiotics. Value assessment methods recognising the value of new antibiotics to the whole health system are needed to help match the size of the required monetary incentives…

Incentives for New Drugs and Vaccines to Tackle Anti-Microbial Resistance

16 May 2017

Resistance to antibiotics is growing. Additional R&D is required. Both Transferable Intellectual Property Rights and Market Entry Rewards should be explored for use in Europe as a regional “pull” incentive….

Patient Preferences for Diagnostic Tests Aimed at Managing Antimicrobial Resistance

7 October 2019

…2017. Time for a Change in How New Antibiotics are Reimbursed: Development of an Insurance Framework for Funding New Antibiotics based on a Policy of Risk Mitigation. Health Policy. DOI….

Antimicrobial Resistance (AMR)

What is AMR?  Antimicrobial Resistance (AMR) occurs when microorganisms such as bacteria, viruses, fungi, and parasites evolve, rendering medications ineffective. Overuse and misuse of antibiotics and antimicrobial drugs contribute to…

New Antimicrobial Drugs: EU Policy Options

4 October 2010

Antimicrobial resistance to drugs is a growing global public health issue. The EU began a discussion in 2009 about which policies can best encourage the development of new antibiotics. New…

Incentives for New Drugs to Tackle Anti-Microbial Resistance

1 May 2017

Resistance to antibiotics is growing, posing a major health risk in rich and poor countries. Additional ways of rewarding R&D are required. Mechanisms designed to encourage companies to undertake R&D…